Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-15

Study Completion Date

2016-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigator's hypothesis is that active injectors will show a partial reduction in markers of immune activation with HCV therapy whereas non-injectors will show a more significant reduction in these markers, and will exhibit levels of immune activation that approach that seen in similarly studied healthy volunteers.This is based on observations that this group of investigators have made. They have shown that individuals who inject drugs have high level of immune activation in blood and tissue. Immune activation or chronic inflammation has been associated with accelerated aging, cardiovascular, renal and liver disease as well as CNS dysfunction. It remains unclear whether increased levels of immune activation are due to non-sterile injection of drugs, chronic infection with Hepatitis C, chronic opiate use, or perhaps combinations of all 3. To understand the potential contribution of infection with Hepatitis C the investigators will compare levels of immune activation pre- and post treatment with an all oral, one pill once daily, interferon sparing treatment of HCV in 2 groups of chronically HCV infected patients- one actively injecting with drugs and the other free of injection for at least 4 months. Immune activation comparisons will also include non-injecting healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Harvoni Treatment Porphyria Cutanea Tarda

NCT03118674

Porphyria Cutanea Tarda Hepatitis C

COMPLETED PHASE2

Hepatitis C Virus(HCV) Heart and Lung Study

NCT02858180

Hepatitis C, Chronic Heart Failure Pulmonary Disease, Chronic Obstructive +1 more

COMPLETED PHASE4

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

NCT02759861

Genotype 1 Hepatitis C Virus

COMPLETED PHASE4

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

NCT02825212

Hepatitis C Cryoglobulinemia

COMPLETED PHASE2/PHASE3

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

NCT00211848

Hepatitis C

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This group of multidisciplinary investigators has discovered increased levels of immune activation among HIV-1-uninfected active injection drug users (IDUs) when compared to non-IDU controls . The vast majority (80%) are also infected with HCV.

Active injectors have high levels of immune activation as measured by sCD14, CD8 co-expression of CD38 and HLA-DR, as well as Type 1 cytokines.

Within months of ceasing injecting, there are observable decreases in some parameters however in general they remain elevated when compared to non-injecting healthy volunteers.

As approximately 80% of these subjects are HCV infected and viremic, these results are confounded as to the cause of the observed increased levels of markers of immune activation- active injection or chronic Hepatitis C. Until recently HCV treatment required the use of IFN which has immunomodulatory activity which would cause perturbations in the markers of immune activation. However the development of direct acting agents (DAA) to treat HCV has revolutionized therapy. In this trial the investigators will employ the once daily FDC formulation of sofosbuvir and ledipasvir to assess changes in markers of immune activation during therapy.

There have been multiple clinical trials of FDC LDV-SOF in patients with Genotype 1 HCV. When taken once daily for 12 weeks, sustained virologic response rates have been very high with response rates nearing 99% in most studies with a 12-week course of therapy.

Common adverse events associated with FDC LDV-SOF in ION-1 include fatigue (21%), headache (25%), nausea (11%), insomnia (8%), asthenia (7%), diarrhea (11%), rash (7%), irritibility (7%), cough (3%), and pruritis (5%).

Ledipasvir undergoes minimal metabolism and expectations are that this medication will have few clinically significant drug-drug interactions. In general, sofosbuvir is considered to have relatively few clinically significant drug-drug interactions, but coadministration of sofosbuvir with the following medications is not recommended because these medications may significantly lower sofosbuvir levels:

Anticonvulsants: carbamazepine, oxycarbazepine, phenobarbital, and phenytoin Antimycobacterials: rifabutin, rifampin, rifapentine Herbal Supplements: St. John's wort HIV Protease Inhibitors: tipranavir-ritonavir Antiarrhythmic Drugs : amiodarone (Cordarone®, Nexterone®, Pacerone®)

Participants will be provided with a 12-week course of FDC LDV-SOF which will provide a near 99% likelihood of a SVR in participants who are adherent to therapy with low likelihood of significant adverse events and drug-drug interactions.

In treating HCV effectively the investigators will measure changes in immune activation and gene expression that accompany HCV treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active injection drug use (IDU)

In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks

Group Type ACTIVE_COMPARATOR

Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

Intervention Type DRUG

Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

Former injection drug use (former IDU)

In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks

Group Type ACTIVE_COMPARATOR

Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

Intervention Type DRUG

Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

Healthy volunteers

HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fixed dose combination ledipasvir/sofosbuvir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ability to give written informed consent in English
2. Age≥18 and ≤55
3. HCV antibody positive
4. HCV RNA \>1,000 copies/mL plasma
5. HCV treatment naive
6. HCV genotype 1a or 1b or mixed type 1
7. AST, ALT \<10x ULN
8. Direct bilirubin \<3.0
9. Platelet count \>50,000
10. Creatinine clearance \>30mL/min as estimated by Cockroft Gault
11. Hemoglobin \>10 if female, \>11 if male
12. Albumin \> 2.8
13. INR\<2.0
14. If Group A: urine dip for opiates + and active injection drug use of heroin defined as injecting at least 3 times per week.
15. If Group B then no IDU for at least 4 months and a negative urine for opiates at screening.
16. Venous access for phlebotomy
17. Willingness to agree to effective contraception during the course of the study.
18. If Group C: - negative urine for opiates at screening

* no recreational drug use for at least 2 years (excluding marijuana)
* HIV, HCV and HBV uninfected

Exclusion Criteria

1. HIV infection
2. Chronic infection with Hepatitis B
3. Uncompensated cirrhosis
4. Required use of:

Anticonvulsants: carbamazepine, oxycarbazepine, phenobarbital, and phenytoin

Antimycobacterials: rifabutin, rifampin, rifapentine

Herbal Supplements: St. John's wort

HIV Protease Inhibitors: tipranavir-ritonavir

Antiarrhythmic Drugs: amiodarone (Cordarone, Nexterone, Pacerone)
5. Any medical condition that in the opinion of the investigator would interfere with study participation and medical adherence
6. Pregnancy/breast feeding

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes